ľ��ֱ��

News Release

Monday, August 12, 2024

Routine lab tests are not a reliable way to diagnose long COVID

NIH-supported study suggests novel biomarkers that distinguish the condition from other ailments are needed.

A ľ��ֱ�� (NIH)-supported study has found that routine lab tests may not be useful in making a long COVID diagnosis for people who have symptoms of the condition. The study, part of and published in the Annals of Internal Medicine, highlights how challenging it can be to identify and diagnose a novel illness such as long COVID.

“Our challenge is to discover biomarkers that can help us quickly and accurately diagnose long COVID to ensure people struggling with this disease receive the most appropriate care as soon as possible,” said David Goff, M.D., Ph.D., director for the Division of Cardiovascular Sciences at the NIH’s National Heart, Lung, and Blood Institute. “Long COVID symptoms can prevent someone from returning to work or school, and may even make everyday tasks a burden, so the ability for rapid diagnosis is key.”

Long COVID encompasses a wide spectrum of symptoms and health conditions that persist for months or years after infection from SARS-CoV-2, the virus that causes COVID-19. No validated clinical biomarkers of long COVID have been found to date, so diagnosing the condition currently requires gathering a detailed medical history and having patients take a physical exam to understand their symptoms, as well as getting laboratory work to rule out other causes.

The researchers conducted the study to determine whether a SARS-CoV-2 infection led to changes in biomarkers, such as platelet counts or protein in the urine, in individuals with a prior SARS-CoV-2 infection, compared to those without prior infection.

More than 10,000 adults — part of the — were recruited at 83 enrolling sites across the U.S. between October 2021 and October 2023. The cohort is demographically diverse, and participants came from a range of geographic locations. Among the 8,746 who had a prior SARS-CoV-2 infection, many had different variants, while 1,348 had never been infected.

The RECOVER Adult Cohort includes both individuals with and without prior SARS-CoV-2 infection and individuals with and without long COVID. Nearly 19% of the study population were identified as having long COVID.

Study participants completed a baseline set of surveys, a physical examination, and 25 standard laboratory blood and urine tests. Participants were then followed throughout the two-year study period, taking surveys every three months and lab tests at six-, 12-, 24-, 36-, and 48-month intervals. The lab tests included a complete blood count panel, metabolic panel, hemoglobin A1c (HbA1c), urinalysis, and urine albumin to creatinine ratio (uACR), among others.

According to the researchers, the lab tests detected markedly few differences in biomarkers between those with prior infection and those without. However, the team did find that prior infection was associated with modest increases in HbA1c, a measure of average blood sugar levels over two to three months, though those increases disappeared after researchers excluded people with pre-existing diabetes.

The researchers also noted slightly elevated increases in uACR, a measure of low kidney function, in participants with previous infection, but those were only seen in a minority of people in that group and may have resulted from severity of the initial infection.

In a secondary analysis, the researchers looked solely at the individuals in the infected group to determine the differences between those who developed long COVID versus those who did not. They used a , which identified 12 symptoms that best identified people with long COVID. Among participants with prior infection, the study found no meaningful differences in lab test results between the two groups. 

“Future work will use RECOVER’s biobank of cohort samples such as blood and spinal fluid, to develop more novel laboratory-based tests that help us better understand the pathophysiology of long COVID,” said Kristine Erlandson, M.D., professor of medicine-infectious disease at the University of Colorado Anschutz Medical Campus, Aurora.

Research reported in this press release was supported by NIH under award numbers OT2HL161841, OT2HL161847, and OT2HL156812. Additional support came from grant R01 HL162373. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. For more information on RECOVER, visit .��������������

About RECOVER: The ľ��ֱ�� Researching COVID to Enhance Recovery (NIH RECOVER) Initiative brings together clinicians, scientists, caregivers, patients, and community members to understand, diagnose, and treat long COVID. RECOVER has created one of the largest and most diverse groups of Long COVID study participants in the world. In addition, RECOVER clinical trials are testing potential interventions across five symptom focus areas. For more information, please visit .

HHS Long COVID Coordination: This work is a part of the (PDF, 1.3 MB), a broader government-wide effort in response to the directing the Secretary for the Department of Health and Human Services to mount a full and effective response to Long COVID. Led by Assistant Secretary for Health Admiral Rachel Levine, the Plan and its companion (PDF, 1.6 MB) lay the groundwork to advance progress in the prevention, diagnosis, treatment, and provision of services for individuals experiencing Long COVID.

About the ľ��ֱ�� (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

NIH…Turning Discovery Into Health^®

###